Dr. Kevin Patrick Ridenhour, MD

Dr. Ridenhour practices at Deaconess Midtown Hospital - Outpatient Therapy in Evansville, Indiana.

Dr. Ridenhour's NPI, 1568462059, was assigned on July 26, 2005. Dr. Ridenhour holds Kentucky license 43969.

Dr. Ridenhour's primary practice is Deaconess Midtown Hospital - Outpatient Therapy, at 600 Mary St, Evansville, IN 47747. The practice phone is (812) 450-3324.

Dr. Ridenhour's primary practice is Deaconess Midtown Hospital - Outpatient Therapy in Evansville, Indiana. Dr. Ridenhour is also affiliated with Deaconess Midtown Hospital. The medical group on file is Fairfield Memorial Hospital - Horizon Healthcare. Dmand AI also links Dr. Ridenhour to 4 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ridenhour practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Ridenhour's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Ridenhour's licenses on file in 2 states: Kentucky and North Carolina.

CMS data shows 1,217 Medicare services from Dr. Ridenhour across 6 procedure codes in 2024, for 380 Medicare patients. Medicare paid $91,396 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 380 Medicare patients who saw Dr. Ridenhour in 2024. The largest group is 65 to 74, with 198 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 10% are also on Medicaid. Their average risk score is 2.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ridenhour's median patient age at 74, with 59% women.

In 2024, Dr. Ridenhour wrote 1,363 Medicare Part D claims for 197 patients. 91% of them were for generic drugs. CMS names the drug for 1,115 of them, across 33 drugs with 11 or more claims each, at $1,022,173 in total drug cost. In 2023, CMS named 774 claims across 24 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Ridenhour for performance year 2024, reported as part of a group. Dr. Ridenhour accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Ridenhour to 2 clinical trials, 2 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Breast Neoplasms and Breast Diseases. Alliance for Clinical Trials in Oncology sponsors the most, 2.

CMS Open Payments shows 386 general payments to Dr. Ridenhour from 60 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 97% of the total. Novartis Pharmaceuticals Corporation paid the most, $956.